Comparative Docking Study of Breast Cancer Drugs and Natural Compounds with DLAT and ATOX1 Proteins

Abstract

Introduction: Breast cancer is common among women, influenced by genetic and environmental factors. Proteins DLAT and ATOX1 contribute to disease. DLAT is part of the pyruvate dehydrogenase complex, involved in metabolism, while ATOX1 regulates copper. Chemotherapy drugs like Epirubicin, Xeloda, and Gemcitabine prevent cancer growth. Natural compounds such as Formononetin and Curcumin also show anticancer potential. Formononetin induces apoptosis and inhibits invasion, while Curcumin has antioxidant and anti-inflammatory effects against cancer.

Methods: In this study, we used molecular docking to explore how these drugs and natural compounds interact with the DLAT and ATOX1 proteins. We obtained the protein structures from the PDB database and the drug structures from PubChem, and docking analysis was performed using PyRx software.

Results: The results showed that all the drugs and plant compounds had a good ability to bind to both proteins, but the binding to DLAT was stronger. Among the drugs, Xeloda performed the best with a binding affinity of -5.7, and among the plant compounds, Formononetin showed the highest effectiveness with a binding affinity of -3.8.

Conclusion: natural compounds like Formononetin and Curcumin may have significant potential as adjuncts in the treatment of breast cancer, though more studies are needed to confirm their effectiveness.

Keywords: Breast cancer, DLAT, ATOX1, Molecular docking

Introduction

Breast Cancer and Molecular Factors in Tumor Progression:

Breast cancer is one of the most significant health challenges for women worldwide and currently represents the most frequently diagnosed cancer among women [1]. Most breast tumors begin in the mammary ducts, and under prolonged exposure to carcinogenic factors, they may evolve into benign growths or even invasive and metastatic carcinomas. The tumor microenvironment, including stromal cells and macrophages, plays a central role in initiating and driving breast cancer progression [2].

Role of DLAT in Mitochondrial Metabolism and Tumor Biology:

Dihydrolipoamide S-acetyltransferase (DLAT) is a mitochondrial protein that serves as the E2 component of the pyruvate dehydrogenase complex, located in the inner mitochondrial membrane (Figure 1.A). Its main function is to participate in glucose metabolism by converting acetyl groups derived from pyruvate into coenzyme A [3].Research indicates that the expression and activity of DLAT vary among different tumor types, suggesting that its role in cancer biology may be context-dependent [4].

Role of ATOX1 in Copper Homeostasis and Cancer Progression:

Antioxidant protein 1 (ATOX1) is a copper metallochaperone that is upregulated in several cancers, including breast, colorectal, uterine, and liver tumors (Figure 1.B), but downregulated in cancers such as cholangiocarcinoma and pancreatic tumors [5].ATOX1 maintains copper balance in cells by delivering copper to ATP7A and ATP7B in the trans Golgi network, which promotes the activation of copper dependent enzymes like ceruloplasmin and lysyl oxidase [6]. Interestingly, nuclear ATOX1 can also function as a transcription factor, contributing to processes such as activin-induced migration and colony formation in cancer cells [7].



Figure 1. Three-dimensional structure of the proteins DLAT and Atox1. a: DLAT protein. b: Atox1 protein.

Epirubicin:

Epirubicin is an anthracycline drug and the 4′-epimer of doxorubicin (Figure 2.A). It has been in clinical use in the United States since 1999 and is now marketed in more than 80 countries for the treatment of breast cancer as well as other malignancies. The anticancer activity of epirubicin involves several mechanisms: intercalation into DNA, inhibition of topoisomerase II, generation of reactive oxygen species, and subsequent disruption of DNA, RNA, and protein synthesis [8]. These same mechanisms are also linked to the cardiotoxic side effects observed with doxorubicin and other anthracyclines.

Xeloda:

Xeloda is an oral fluoropyrimidine carbamate (Figure 2.B) and is currently the only approved treatment for patients whose disease has progressed following anthracycline and taxane-based therapy. It is designed to be selectively activated within tumor tissue, where it generates therapeutically active concentrations of 5-fluorouracil (5-FU) [9–11]. Because thymidine phosphorylase the enzyme responsible for the final activation step of Xeloda is more active in tumors than in normal tissues, intratumoral levels of 5-FU are higher than those in plasma. This tumor-selective activation, along with reduced systemic exposure, improves the therapeutic index of Xeloda [12,13].

Gemcitabine:

Gemcitabine is one of the most active agents used against breast cancer and has received full approval for its clinical application (Figure 2.C). It is a deoxycytidine analog with potent anticancer activity and a favorable therapeutic index [14]. Once administered, gemcitabine is either deaminated by deoxycytidine deaminase into an inactive metabolite, 2′,2′ difluoro deoxy uridine (dFdU), or phosphorylated by deoxycytidine kinase into its active form, dFdC monophosphate (dFdCMP). This metabolite is subsequently converted into diphosphate and triphosphate derivatives, which incorporate into DNA and cause chain termination. Although gemcitabine shares structural and mechanistic similarities with cytarabine (Ara-C), it demonstrates a broader spectrum of antitumor activity [15].



Figure 2. Three-dimensional structures of the drugs Epirubicin, Xeloda, and Gemcitabine. a: Epirubicin b: Xeloda c: Gemcitabine.

Natural Products in Cancer Therapy:
Currently, about 75% of clinically used anticancer drugs are derived from natural sources such as plants, animals, and microorganisms [16]. Since ancient times, plants have been widely used in traditional medicine for wound healing, disease treatment, and general health maintenance [17].

Formononetin is an O-methylated isoflavone with a molecular weight of 268.268 g/mol (Figure 3.A). It is commonly found in legumes, various clover species particularly red clover (Trifolium pratense L.) and in the traditional Chinese medicinal plant Astragalus membranaceus (Fisch) [18]. In cancer cells, including breast cancer, formononetin regulates the balance between pro-apoptotic and anti-apoptotic proteins of the Bcl-2 family. Studies demonstrate that formononetin induces dose-dependent alterations in the Bax/Bcl-2 protein ratio, promoting apoptosis in tumor cells [19].

Curcumin, a polyphenol extracted from Curcuma species (Figure 3.B), is well known for its broad anticancer activity and its ability to interfere with several hallmarks of tumor progression [20]. One key mechanism involves inhibition of the transcription factor NF-κB, which controls processes such as cell proliferation, angiogenesis, metastasis, apoptosis, and resistance to therapy [21]. Curcumin suppresses NF-κB activation through inhibition of IκB kinase signaling.

Additionally, curcumin downregulates Cyclin D1, an oncogenic driver of cell cycle progression and proliferation that is often overexpressed in cancers [22,23]. Both in vitro and in vivo studies have shown that curcumin enhances TP53 expression and promotes apoptosis [24]. It also prevents phosphorylation of retinoblastoma protein (RB), a key tumor suppressor regulating the cell cycle [25]. Moreover, curcumin inhibits signaling mediated by epidermal growth factor (EGF) and its receptor EGFR, both of which are frequently overexpressed in breast tumors and contribute to cancer progression [26,27].



Figure 3. Three-dimensional structures of formononetin and curcumin. a: Formononetin. b: Curcumin

Molecular Docking:

Molecular docking has become an important tool in modern in-silico drug development. This method predicts how a small molecule interacts with a protein at the atomic level [28]. By doing so, it helps researchers analyze how compounds, including nutrients or drugs, bind to target proteins and provides insight into the biochemical processes involved [29]. Docking is a structure-based

approach, which means it requires a high-resolution three-dimensional structure of the target protein. Such structures are usually obtained through X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy [30–32].

In this study, we aim, for the first time, to use molecular docking to compare the binding affinities of commonly used breast cancer drugs, including Epirubicin, Xeloda and Gemcitabine, alongside two plant-derived compounds, formononetin and curcumin, to two key proteins, DLAT and ATOX1. This innovative approach allows for the identification of potential interactions between conventional drugs and plant compounds with critical molecular targets in breast cancer, providing new insights for the development of combination therapies.

Material and Methods

To perform the docking process, we need the three-dimensional structure of proteins, drugs, and plant compounds. First, we entered the PDB site at rcsb.org and searched for the name of the Atox1 protein in the search section and saved the desired protein in the PDB format. We did the same for the DLAT protein. Then, with the help of the pubchem site at pubchem.ncbi.nlm.nih.gov, we saved the three-dimensional structure of the drugs Epirubicin, Xeloda, and Gemcitabine and the plant compounds Formononetin and Curcumin in the SDF format. The protein saved from the PDB site is in an impure form, and we used the chimera software version 1.8 to purify and make the desired modifications. Since the DLAT protein consists of three chains, we selected the A chain, which was larger, and deleted the other chains using the software's select option, selecting chain, then the action option, selecting the atom binding option, and the delete option. The Atox1 protein also consists of two chains, which we selected chain B and deleted chain A. To make modifications, including adding hydrogen ions and charge flow, removing excess molecules and water from the selected chain, we used the Tools option, then selected the Surface Binding Analysis option, then the Dock Prep option, and checked all the desired changes from the opened menu. After confirming the protein structure, it is ready for docking (Figure 3). Then we saved the proteins in PDB format, and in the next step, we loaded the proteins individually into the Pyrx software version 0.8 and defined the protein as a macromolecule in the software. For this, we used the File option, then the Load Molecule option. When the name and shape of the protein appeared in the software, we clicked on the protein name and selected Autodock Make Macromolecule, and then loaded the desired drugs and herbal compounds one by one in the SDF format into the Pyrx software as ligands. For this, we used the File option and then the Import option. In order to apply the changes made to the protein to the drug, we clicked on the molecular formula of the drug or herbal compound that we entered into the software and selected the convert to PDBQT option. After minimizing, we docked the protein and drug and set the desired coordinates for the drug-protein binding so that the center of the search grid for the DLAT protein was defined at X: 59.5815, Y: 28.7394, Z: 65.9339 and for the ATOX1 protein at X: 33.8357, Y: 25.5754, Z: 39.585, and the Forward option was executed. After a few minutes, the software provided a table of binding affinity values. The interpretation of the results was as follows: the more negative the binding affinity value

(for example, less than -5), the stronger the binding between the drug and the protein.



Figure 4. Proteins DLAT and Atox1 after modifications in Chimera software. a. Chain A of the DLAT protein. b. Chain B of the Atox1 protein.

Results

The results of docking between the protein ATOX1 and the drug Xeloda are presented in Table 1. Similarly, the results of docking between the protein DLAT and the drug Xeloda are presented in Table 2.

Table 1: Results of Molecular Docking Between ATOX1 Protein and the Drug Xeloda

Mode	RMSD Upper (ATOX1)	RMSD Lower (ATOX1)	Affinity (ATOX1)
0	0.000	0.000	-5.1
1	9.225	7.970	-5.0
2	10.022	8.181	-4.9
3	10.495	3.837	-4.9
4	9.928	8.216	-4.9
5	8.775	3.332	-4.7
6	8.771	5.313	-4.6
7	20.698	18.336	-4.6
8	9.138	2.439	-4.6

Table 2: Results of Molecular Docking Between DLAT Protein and the Drug Xeloda

Mode	RMSD Upper (DLAT)	RMSD Lower (DLAT)	Affinity (DLAT)
0	0.000	0.000	-7.5

1	2.314	1.517	-6.6
2	22.744	21.020	-6.5
3	2.004	1.426	-6.5
4	2.701	1.660	-6.4
5	20.706	19.497	-6.1
6	21.826	20.831	-6.0
7	23.079	21.243	-6.0
8	2.828	1.644	-6.0

The results of the docking between the protein ATOX1 and the drug Gemcitabine, are presented in Table 3. Similarly, the results of the docking between the protein DLAT and the drug Gemcitabine, are presented in Table 4.

Table 3: Results of Molecular Docking Between ATOX1 Protein and the Drug Gemcitabin

Mode	RMSD Upper (ATOX1)	RMSD Lower (ATOX1)	Affinity (ATOX1)
0	0.000	0.000	-5.4
1	4.557	2.911	-5.0
2	4.346	2.394	-4.9
3	4.909	3.100	-4.9
4	1.770	1.593	-4.6
5	12.535	11.476	-4.4
6	3.382	2.094	-4.3
7	14.778	13.508	-4.2
8	13.357	11.841	-4.1

Table 4: Results of Molecular Docking Between DLAT Protein and the Drug Gemcitabin

Mode	RMSD Upper (DLAT)	RMSD Lower (DLAT)	Affinity (DLAT)
0	0.000	0.000	-6.5
1	7.023	4.484	-6.3
2	5.501	3.684	-6.2
3	6.280	4.225	-5.9
4	5.262	2.984	-5.8
5	21.518	20.352	-5.8
6	21.356	20.089	-5.7

7	21.436	20.285	-5.6
8	20.689	19.633	-5.3

The results of the docking analysis between the DLAT protein and the drug Epirubicin, are presented in Table 5. Similarly, the results of the docking analysis between the ATOX1 protein and the drug Epirubicin, are presented in Table 6.

Table 5: Results of Molecular Docking Between DLAT Protein and the Drug Epirubicin

Mode	RMSD Upper (DLAT)	RMSD Lower (DLAT)	Affinity (DLAT)
0	0.000	0.000	-5.8
1	5.599	2.871	-5.5
2	14.370	10.963	-5.3
3	5.193	2.509	-4.7
4	6.813	2.543	-4.6
5	17.697	13.946	-4.6
6	13.138	9.389	-4.5
7	16.923	13.055	-4.3
8	16.092	12.095	-4.1

Table 6: Results of Molecular Docking Between ATOX1 Protein and the Drug Epirubicin

Mode	RMSD Upper (ATOX1)	RMSD Lower (ATOX1)	Affinity (ATOX1)
0	0.000	0.000	-5.6
1	12.553	7.619	-5.5
2	11.019	7.183	-5.4
3	6.102	2.689	-5.4
4	12.283	7.657	-5.3
5	7.476	4.337	-5.3
6	11.138	8.349	-5.3
7	5.127	2.371	-5.2
8	5.802	3.213	-5.1

The results of docking between the ATOX1 protein and formononetin, are presented in Table 7. Similarly, the results of docking between the DLAT protein and formononetin, are presented in Table 8.

Table 7: Results of Molecular Docking Between ATOX1 Protein and the Formononetin

Mode	RMSD Upper (ATOX1)	RMSD Lower (ATOX1)	Affinity (ATOX1)
0	0.000	0.000	-5.4
1	1.886	0.751	-5.1
2	10.795	8.228	-5.0
3	10.62	9.054	-4.9
4	10.746	8.58	-4.9
5	2.243	2.096	-4.9
6	12.325	9.354	-4.7
7	12.734	9.801	-4.6
8	14.531	13.34	-4.6

Table 8: Results of Molecular Docking Between DLAT Protein and the Formononetin

Mode	RMSD Upper (DLAT)	RMSD Lower (DLAT)	Affinity (DLAT)
0	0.000	0.000	-8.3
1	2.328	1.376	-8.3
2	3.664	2.499	-7.5
3	22.949	20.777	-6.2
4	23.25	21.161	-6.2
5	19.917	18.061	-6.0
6	23.187	20.948	-6.0
7	22.114	20.95	-5.7
8	18.633	16.007	-5.6

The results of the docking analysis of the ATOX1 protein with curcumin, are presented in Table 9. Similarly, the results of the docking analysis of the DLAT protein with curcumin, are presented in Table 10.

Table 9: Results of Molecular Docking Between ATOX1 Protein and the Curcumin

Mode	RMSD Upper (ATOX1)	RMSD Lower (ATOX1)	Affinity (ATOX1)
0	0.000	0.000	-5.8
1	11.602	7.607	-5.8
2	11.701	7.624	-5.8
3	12.949	9.714	-5.7
4	8.481	3.969	-5.6
5	12.788	8.622	-5.5
6	9.699	2.98	-5.4
7	10.756	6.818	-5.4
8	10.411	6.834	-5.4

Table 10: Results of Molecular Docking Between DLAT Protein and the Curcumin

Mode	RMSD Upper (DLAT)	RMSD Lower (DLAT)	Affinity (DLAT)
0	0.000	0.000	-8.2
1	7.74	0.595	-8.1
2	22.028	20.25	-6.8
3	22.669	20.116	-6.7
4	22.017	20.241	-6.7
5	22.208	20.36	-6.6
6	7.523	2.398	-6.6
7	22.002	20.042	-6.6
8	23.197	20.967	-6.2

Discussion

In this study, the interactions of the anticancer drugs epirubicin, Xeloda, and gemcitabine, as well as the natural compounds curcumin and formononetin, with the human proteins DLAT and ATOX1 were investigated using molecular docking. According to the results obtained from the PyRx software, more negative binding values indicate stronger interactions between the compound and the protein. The findings showed that all three studied drugs were able to bind to both proteins, but their binding intensity was higher with DLAT. Among the drugs, Xeloda, with a binding affinity of -7.5 kcal/mol, showed the strongest effect and binding strength on DLAT, indicating the high potential of this drug to target DLAT in the treatment of breast cancer. This result emphasizes the importance of DLAT as a therapeutic target in breast cancer. The natural compounds formononetin and curcumin also showed strong binding to both proteins, with stronger interactions with DLAT (formononetin: -8.2 kcal/mol, curcumin: -8.3 kcal/mol), surpassing the tested drugs. These results suggest that these natural compounds can exert significant inhibitory effects on DLAT and may serve as potential complementary or alternative therapeutic agents. Their binding to Atox1 was also

favorable, although less than DLAT, suggesting that DLAT is the primary and more effective target of these compounds. Comparison with previous studies suggests that curcumin and formononetin exert anticancer effects by inhibiting key proteins such as DLAT, which is consistent with our data. These findings support the notion that natural compounds may enhance therapeutic efficacy when combined with chemotherapeutic drugs. Overall, the results of this study suggest that DLAT could be an important molecular target for breast cancer treatment and that natural compounds have stronger inhibitory potential. These findings may provide a basis for further experimental studies and the design of combination therapies.

Conclusion

The results of this study indicate that plant-derived compounds have the potential to be used as anticancer agents. Molecular docking can facilitate the design of targeted drugs, selecting more effective treatments. This technique is very valuable in the design of new drugs and reduces the time and resources required for drug development and testing. It also allows pharmaceutical companies to evaluate drug-receptor interactions bioinformatically before production and use active plant compounds in drug development and design of new drugs. However, docking results need to be aligned with laboratory experiments and the simultaneous use of natural compounds with breast cancer drugs needs to be evaluated and tested further.

Conflict of Interest

The authors declare that there are no conflicts of interest.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249. https://pubmed.ncbi.nlm.nih.gov/33538338/
2. Sonnenschein C, Soto AM. Carcinogenesis explained within the context of a theory of organisms. Prog Biophys Mol Biol 2016; 122: 70–76. https://pubmed.ncbi.nlm.nih.gov/27498170/
3. Ganetzky R, McCormick EM, Falk MJ. Primary pyruvate dehydrogenase complex deficiency overview. GeneReviews [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK571223/
4. Goh WQ, Ow GS, Kuznetsov VA, et al. DLAT subunit of the pyruvate dehydrogenase complex is upregulated in gastric cancer: implications in cancer therapy. Am J Transl Res 2015; 7: 1140–26279757. https://pubmed.ncbi.nlm.nih.gov/26279757/
5. Blockhuys S, Celauro E, Hildesjö C, et al. Defining the human copper proteome and analysis of its expression variation in cancers. Metallomics 2017; 9: 112–123. https://pubmed.ncbi.nlm.nih.gov/27942658/
6. Denoyer D, Masaldan S, La Fontaine S, et al. Targeting copper in cancer therapy: ‘Copper That Cancer’. Metallomics 2015; 7: 1459–1476. https://pubmed.ncbi.nlm.nih.gov/26313539/

7. Jana A, Das A, Krett NL, et al. Nuclear translocation of Atox1 potentiates activin A-induced cell migration and colony formation in colon cancer. PLoS One; 15. Epub ahead of print 1 January 2020. https://pubmed.ncbi.nlm.nih.gov/31961892/
8. Khasraw M, Bell R, Dang C. Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. Breast 2012; 21: 142–149. https://pubmed.ncbi.nlm.nih.gov/22260846/
9. Hong RX, Xu F, Xia W, et al. Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial. J Clin Oncol 2025; 43: 1314–1324. https://pubmed.ncbi.nlm.nih.gov/39746176/
10. Park IH, Im SA, Jung KH, Sohn JH, Park YH, Lee KS, Sim SH, Park KH, Kim JH, Nam BH, Kim HJ, Kim TY, Lee KH, Kim SB, Ahn JH, Lee S, Ro J. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). Cancer Res Treat. 2019 Jan;51(1):43-52. https://pubmed.ncbi.nlm.nih.gov/29458237/
11. Ganesh JN, Buss AC, Harris M. Meta-analysis of docetaxel plus capecitabine versus docetaxel plus epirubicin in HER2-negative breast cancer. BMC Womens Heal 2025; 25: 123. https://pmc.ncbi.nlm.nih.gov/articles/PMC6360291/
12. Wang S. Role and efficacy of capecitabine in anthracycline-free chemotherapy regimens. J Cancer Res Clin Oncol 2023; 149: 1025–1034. https://pubmed.ncbi.nlm.nih.gov/37891407/
13. Cheraghi M, al. et. Pilot randomized trial comparing epirubicin-oxaliplatin-capecitabine (EOX) versus docetaxel-cisplatin-5-fluorouracil (TCF) as neoadjuvant chemotherapy in advanced gastric cancer. J Inflamm Dis 2024; 28: e154396. https://www.researchgate.net/publication/392363384_Pilot_Study_Comparing_Epirubicin_Oxaliplatin_Capecitabine_EOX_and_Docetaxel_Cisplatin_and_5-Fluorouracil_TCF_Regimens_in_Neoadjuvant_Chemotherapy_for_Gastric_Cancer_Patients
14. Nemati M, Xia ETA. Gemcitabine: immunomodulatory or immunosuppressive? Front Oncol 2025; 15: 123456. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1536428/full
15. Koltai T. Resistance to gemcitabine in pancreatic ductal adenocarcinoma: molecular mechanisms and emerging strategies. Cancers (Basel) 2022; 14: 2486. https://pubmed.ncbi.nlm.nih.gov/35626089/
16. Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2016; 79: 629–661. https://pubmed.ncbi.nlm.nih.gov/26852623/
17. Tan LTH, Lee LH, Yin WF, et al. Traditional uses, phytochemistry, and bioactivities of Cananga odorata (Ylang-Ylang). Evid Based Complement Altern Med 2015; 2015: 896314. https://pubmed.ncbi.nlm.nih.gov/26294929/
18. Heinonen SM, Wähälä K, Adlercreutz H. Identification of urinary metabolites of the red clover isoflavones formononetin and biochanin A in human subjects. J Agric Food Chem 2004; 52: 6802–6809. https://pubmed.ncbi.nlm.nih.gov/15506819/
19. Zhang X, Ni Q, Wang Y, et al. Synergistic anticancer effects of formononetin and temozolomide on glioma C6 cells. Biol Pharm Bull 2018; 41: 1194–1202. https://pubmed.ncbi.nlm.nih.gov/29848900/

20. Choudhuri TS, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressing cells at G2 phase via p53-dependent mechanism. J Biol Chem 2005; 280: 20059–20068. https://pubmed.ncbi.nlm.nih.gov/15738001/
21. Kunnumakkara AB, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199–225. https://pubmed.ncbi.nlm.nih.gov/18479807/
22. Tsyetkoy P, Asher G, Reiss V, et al. Inhibition of NAD(P)H: quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA 2005; 102: 5535–5540. https://pubmed.ncbi.nlm.nih.gov/15809436/
23. Aggarwal BB, Banerjee S, Bharadwaj U, et al. Curcumin induces degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 2007; 73: 1024–1032. https://pubmed.ncbi.nlm.nih.gov/17240359/
24. Zhan Y, Chen Y, Liu R, et al. Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling. Arch Pharmacal Res 2014; 37: 1086–1095. https://pubmed.ncbi.nlm.nih.gov/24318305/
25. Sun XD, Liu XE, Huang DS. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Molec Med Rep 2012; 6: 1267–1270. https://pubmed.ncbi.nlm.nih.gov/23023821/
26. Ataie A, Shadifar M, Ataee R. Polyphenolic Antioxidants and Neuronal Regeneration. Basic Clin Neurosci 2016; 7: 81–90. https://pmc.ncbi.nlm.nih.gov/articles/PMC4892323/
27. Gaedeke J, Noble NA, Border WA. Curcumin blocks multiple sites of the TGF-□ signaling cascade in renal cells. Kidney Int 2004; 66: 112–120. https://pubmed.ncbi.nlm.nih.gov/15200418/
28. Sahoo RN, Pattanaik S, Pattnaik G, et al. Review on the use of Molecular Docking as the First Line Tool in Drug Discovery and Development. Indian J Pharm Sci; 84. Epub ahead of print 2022. https://www.ijpsonline.com/articles/review-on-the-use-of-molecular-docking-as-the-first-line-tool-in-drug-discovery-and-development-4751.html
29. Meng XY, Zhang HX, Mezei M, et al. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011; 7: 146–157. https://pubmed.ncbi.nlm.nih.gov/21534921/
30. Bijak V, Minor W. The current role and evolution of X-ray crystallography in drug discovery and development. Expert Opin Drug Discov 2023; 18: 1221–1230. https://pubmed.ncbi.nlm.nih.gov/37592849/
31. Sugiki T, Kobayashi N, Fujiwara T. Modern technologies of solution nuclear magnetic resonance spectroscopy for three-dimensional structure determination of proteins open avenues for life scientists. Comput Struct Biotechnol J 2017; 15: 328–339. https://pubmed.ncbi.nlm.nih.gov/28487762/
32. Nakane T, Kotecha A, Sente A, et al. Single-particle cryo-EM at atomic resolution. Nature 2020; 587: 152–156. https://pubmed.ncbi.nlm.nih.gov/33087931/